MedTrace Logo

Comparative Study of Tranexamic Acid, Estrogen for Treatment AUB in DMPA Users

NCT06067217 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2023-11-18

No results posted yet for this study

Summary

Abnormal uterine bleeding is the most common problems to discontinue Depo-medroxyprogesterone acetate (DMPA) in Thailand. This clinical trial use to provide drug to stop abnormal uterine bleeding from DMPA

Conditions

  • Abnormal Uterine Bleeding
  • Tranexamic Acid
  • Estrogen
  • Depot Medroxyprogesterone Acetate

Interventions

DRUG

Tranexamic acid 250 mg oral tablet

Compare between tranexamic acid and progynova to stop abnormal uterine bleeding in DMPA users

DRUG

Progynova 1 mg oral tablet

Compare between tranexamic acid and progynova to stop abnormal uterine bleeding in DMPA users

Sponsors & Collaborators

  • Department of Medical Services Ministry of Public Health of Thailand

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-09-30
Primary Completion
2024-08-01
Completion
2024-08-30

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06067217 on ClinicalTrials.gov